Hantz Financial Services Inc. Has $3 Million Position in AstraZeneca PLC (NASDAQ:AZN)

Hantz Financial Services Inc. lifted its stake in AstraZeneca PLC (NASDAQ:AZN) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,726 shares of the company’s stock after acquiring an additional 1,212 shares during the quarter. Hantz Financial Services Inc.’s holdings in AstraZeneca were worth $2,996,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC increased its position in AstraZeneca by 112.4% in the 2nd quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after purchasing an additional 7,241 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in AstraZeneca by 39.1% in the second quarter. The Manufacturers Life Insurance Company now owns 206,446 shares of the company’s stock worth $16,104,000 after buying an additional 58,039 shares during the last quarter. NewEdge Advisors LLC raised its position in AstraZeneca by 13.2% during the second quarter. NewEdge Advisors LLC now owns 49,589 shares of the company’s stock valued at $3,867,000 after acquiring an additional 5,779 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its stake in AstraZeneca by 2.1% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 86,163 shares of the company’s stock valued at $6,720,000 after acquiring an additional 1,737 shares during the last quarter. Finally, Truist Financial Corp increased its stake in shares of AstraZeneca by 4.6% during the 2nd quarter. Truist Financial Corp now owns 250,478 shares of the company’s stock worth $19,535,000 after purchasing an additional 11,074 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Up 1.4 %

AstraZeneca stock opened at $71.24 on Friday. The firm has a market cap of $220.92 billion, a price-to-earnings ratio of 34.09, a P/E/G ratio of 1.13 and a beta of 0.46. The firm has a fifty day moving average price of $66.83 and a two-hundred day moving average price of $73.99. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.87 EPS. As a group, analysts forecast that AstraZeneca PLC will post 4.12 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.